MeiraGTx (MGTX) Stock Price, News & Analysis

Company Overview

MeiraGTx Holdings plc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes to targeted tissues and address the underlying causes of disease.

Its research and development activities have focused primarily on disorders of the central nervous system, including neurodegenerative diseases, as well as retinal and salivary-gland conditions. MeiraGTx is also developing a riboswitch platform designed to control the production of therapeutic proteins with orally administered small molecules, potentially allowing gene therapy activity to be adjusted after treatment.

Founded in 2015, MeiraGTx has developed operations spanning the United States and the United Kingdom, including research, clinical development and manufacturing capabilities. Alexandria Forbes has served as the company's president and chief executive officer since its founding. The company's therapies remain investigational and are subject to clinical testing and regulatory review.

Key Stats

• Today's Range: $9.08 to $9.72
• 50-Day Range: $9.21 to $14.97
• 52-Week Range: $6.62 to $15.35
• Volume: 595,503 shs
• Average Volume: 953,987 shs
• Market Capitalization: $884.53 million
• P/E Ratio: 12.97
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Moderate Buy

MeiraGTx Stock Analysis - MarketRank™

MeiraGTx scored higher than 62% of companies evaluated by MarketBeat, and ranked 320th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MeiraGTx has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

MeiraGTx has a consensus price target of $24.00, representing about 160.6% upside from its current price of $9.21.

Amount of Analyst Coverage

MeiraGTx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MeiraGTx are expected to decrease in the coming year, from $0.30 to ($2.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MeiraGTx is 12.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of MeiraGTx is 12.97, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.89.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.74% of the float of MeiraGTx has been sold short.

Short Interest Ratio / Days to Cover

MeiraGTx has a short interest ratio ("days to cover") of 5.04.

Change versus previous month

Short interest in MeiraGTx has recently increased by 49.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MeiraGTx does not currently pay a dividend.

Dividend Growth

MeiraGTx does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.42

News Sentiment

MeiraGTx has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for MeiraGTx this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for MGTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,710,812.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of MeiraGTx is held by insiders.

Percentage Held by Institutions

67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/24/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MGTX
• CIK: 1735438
• Web: www.meiragtx.com
• Phone: (646) 860-7985
• Fax: N/A
• Employees: 393
• Year Founded: 2015

Price Target and Rating

• Average Price Target for MeiraGTx: $24.00
• High Price Target: $35.00
• Low Price Target: $16.00
• Potential Upside/Downside: +160.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.71
• Trailing P/E Ratio: 12.97
• Forward P/E Ratio: 30.70
• P/E Growth: N/A
• Net Income: -$114.20 million
• Net Margins: 19.87%
• Pretax Margin: 20.45%
• Return on Equity: 283.85%
• Return on Assets: 29.39%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 3.76
• Quick Ratio: 3.76

Sales & Book Value

• Annual Sales: $81.39 million
• Price / Sales: 10.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -131.57

Miscellaneous

• Outstanding Shares: 96,040,000
• Free Float: 88,936,000
• Market Cap: $884.53 million
• Optionable: Optionable
• Beta: 1.35